Showing results (221-230 of 410) with videos related to
Sort By:
Pageof 41
Nature Medicine|June 8, 2019
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patientsRyan J Sullivan, Omid Hamid, Rene Gonzalez, et al.Cancer Immunology Research|May 20, 2017
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint BlockadeJun Zhou, Kathleen M Mahoney, Anita Giobbie-Hurder, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 1, 2017
Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiationLuke R G Pike, Andrew Bang, Patrick Ott, et al.Cancer Immunology Research|May 28, 2015
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell CarcinomaMarcella Callea, Laurence Albiges, Mamta Gupta, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of AtezolizumabOmid Hamid, Luciana Molinero, Christopher R Bolen, et al.Nature Medicine|June 8, 2019
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanomaAntoni Ribas, Donald Lawrence, Victoria Atkinson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2016
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory MelanomaDanny N Khalil, Michael A Postow, Nageatte Ibrahim, et al.Cancer Immunology Research|December 23, 2016
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint TherapyXinqi Wu, Anita Giobbie-Hurder, Xiaoyun Liao, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2017
Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical TrialMark A Exley, Phillip Friedlander, Nadia Alatrakchi, et al.Nature Genetics|November 24, 2020
Integrated molecular drivers coordinate biological and clinical states in melanomaJake R Conway, Felix Dietlein, Amaro Taylor-Weiner, et al.Pageof 41